pubmed.ncbi.nlm.nih.gov

Psychedelics for the treatment of depression, anxiety, and existential distress in patients with a terminal illness: a systematic review - PubMed

  • ️Thu Aug 04 2022

Review

Psychedelics for the treatment of depression, anxiety, and existential distress in patients with a terminal illness: a systematic review

Nina Schimmers et al. Psychopharmacology (Berl). 2022 Jan.

Erratum in

Abstract

Background: Terminally ill patients may experience existential distress, depression, or anxiety, limiting quality of life in the final stage. Existing psychotherapeutic or pharmacological interventions have (time) limited efficacy. Psychedelic treatment may be a safe and effective alternative treatment option.

Aim: Systematically review studies on psychedelic treatment with and without psychotherapy for existential distress, depression, and anxiety in terminally ill patients.

Methods: Medline, PsycINFO, and Embase were searched for original-data studies on the treatment of depression, anxiety, and existential distress with classical or a-typical psychedelics in patients with a terminal illness, using Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines.

Results: A total of 1850 records were screened, and 33 articles were included in this review: 14 studies on classical psychedelics (DPT, LSD, and psilocybin) and 19 studies on atypical psychedelics (MDMA and ketamine). Results of early pre-post studies are promising but have serious methodological flaws. Recent (controlled) trials with LSD, psilocybin, ketamine, and MDMA are of higher methodological quality and indicate positive effects on existential and spiritual well-being, quality of life, acceptance, and reduction of anxiety and depression with few adverse and no serious adverse effects.

Conclusions: Both classical and a-typical psychedelics are promising treatment options in patients with terminal illness. To draw final conclusions on effectiveness and safety of psychedelics, we need larger high-quality studies for classical psychedelics and MDMA. Ketamine studies should pay more attention to existential dimensions of well-being and the psychotherapeutic context of the treatment.

Keywords: Anxiety; Depression; Existential distress; Life-threatening disease; Psychedelics.

© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Agin-Liebes GI, Malone T, Yalch MM et al (2020) Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer. J Psychopharmacol 34(2):155–166 - PubMed - DOI
    1. Akechi T, Okuyama T, Onishi J, et al. (2008) Psychotherapy for depression among incurable cancer patients. Cochrane Database Syst Rev. Epub ahead of print 2008/04/22. https://doi.org/10.1002/14651858.CD005537.pub2.(2 ): CD005537.
    1. Anderson BT, Danforth A, Daroff PR et al (2020) Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: an open-label safety and feasibility pilot study. EClinicalMedicine. https://doi.org/10.1016/j.eclinm.2020.100538 - DOI - PubMed - PMC
    1. Andrew BN, Guan NC, Jaafar NRN (2018) The use of methylphenidate for physical and psychological symptoms in cancer patients: a review. Curr Drug Targets 19(8):877–887 - PubMed - DOI
    1. Bahji A, Forsyth A, Groll D, et al. (2020) Efficacy of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for posttraumatic stress disorder: a systematic review and meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry 96: 109735.

Publication types

MeSH terms

Substances

LinkOut - more resources